Effects of empagliflozin in patients at risk of heart failure: the <i>empire prevent metabolic</i> trial
In high-risk patients with overweight or obesity, treatment with empagliflozin resulted in a potentially favourable reduction in eECV compared to placebo. Meanwhile, the drug did not affect EAT mass.
Authors
- Nina Nouhravesh (ORCID: https://orcid.org/0000-0002-4891-7358)
- Julie Lyng Forman (ORCID: https://orcid.org/0000-0001-7368-0869)
- Camilla Andersen (ORCID: https://orcid.org/0000-0002-6659-154X)
- Massar Omar
- Caroline Kistorp (ORCID: https://orcid.org/0000-0002-3019-6775)
- Filip Soeskov Davidovski (ORCID: https://orcid.org/0000-0002-6642-416X)
- Christian Tuxen
- Julie Hempel Larsen (ORCID: https://orcid.org/0000-0002-2326-5736)
- Filip K. Knop (ORCID: https://orcid.org/0000-0002-2495-5034)
- Jacob Eifer Møller (ORCID: https://orcid.org/0000-0003-2873-5845)
- J. D. Jensen
- Morten Schou
- Per Lav Madsen
- Lars Køber
Institutions
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Novo Nordisk (Denmark) (DK)
- Frederiksberg Hospital (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1093/eurjpc/zwag010
- Citations
- 1
- Primary Topic
- Cardiovascular Disease and Adiposity
- Type
- article
- Field-Weighted Citation Impact
- 30.07